Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Bird Flu Expert Working on Vaccine that Protects Against Multiple Strains

Published: Friday, May 10, 2013
Last Updated: Friday, May 10, 2013
Bookmark and Share
As the bird flu outbreak in China worsens, a Purdue University expert is working on vaccines that offer broader protection against multiple strains of the virus.

The World Health Organization warned in a news conference that the virus behind the current outbreak, H7N9, is one of the most lethal seen in recent years. There have been 32 reported deaths from this avian influenza virus.

Suresh Mittal, a professor of comparative pathobiology in Purdue's College of Veterinary Medicine, has developed a new vaccination method that incorporates genes from multiple strains of the virus and creates protection that could persist through different mutations, he said.

"Avian influenza viruses are moving targets that rapidly evolve and evade vaccines that are specific to a predicted strain," Mittal said. "We need a vaccine that protects against a spectrum of strains to prepare for a potential pandemic. Such a vaccine may not offer full protection from the strain that pops up, but even partial protection could save lives and buy time to create a more effective vaccine."

Mittal created vaccines for past strains of bird flu and continues to collaborate with the Centers for Disease Control and Prevention.

"The strain responsible for the current outbreak appears not to be easily transmitted from person to person, which occurs effectively in a pandemic situation," he said. "Fortunately, avian influenza in humans tends to replicate deep in the lungs where it can't easily get out through coughing. However, the more people this virus infects, the more chances it has to evolve. It is important to keep a close watch on this outbreak."

The H7N9 is a new strain of avian influenza virus with the potential to infect humans, he said.

Mittal's method uses a harmless adenovirus as a vector to deliver avian influenza virus genes into the body where they create a two-fold immune response of antibody and cell-based protection. The adenovirus vector-infected  host cells produce infleunza proteins that lead to the creation of antibodies and special T-cells primed to kill the virus and any cells infected by it.

Any genes important to avian influenza virus protection can be incorporated into the adenovirus vector, and it can be designed to expose the immune system to  both the surface and internal components of the virus. In this way the immune system can be primed to recognize portions of the virus that predominately remain the same across all strains and those that are more difficult for the virus to change as it adapts to the immune system attack, he said.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Zika Virus Structure Revealed
Team at Purdue becomes the first to determine the structure of the Zika virus, which reveals insights critical to the development of effective antiviral treatments and vaccines.
Monday, April 04, 2016
Purdue Researcher's New 'Tool for the Organic Chemist Toolbox' Licensed to Sigma-Aldrich
U.S. patent for a safer, easier and "greener" method to incorporate fluorine into organic compounds has been licensed to a subsidiary of Sigma-Aldrich Corporation.
Friday, May 24, 2013
Discovery Points to New Approach to Fight Dengue Virus
Researchers have discovered that rising temperature induces key changes in the dengue virus when it enters its human host, suggests new approach for designing vaccines against the aggressive mosquito-borne pathogen.
Monday, April 15, 2013
Researcher Taking Shot at Flu Vaccine That's More Effective, Easier to Make
In the midst of an unusually deadly flu season and armed with a vaccine that only offers partial protection, researcher is working on a flu vaccine that overcomes the need to predict which strains will hit each year.
Monday, February 11, 2013
Scientific News
Molecular Mechanism For Generating Specific Antibody Responses Discovered
Study could spur more ways to treat autoimmune disease, develop accurate vaccines.
Understanding Female HIV Transmission
Glowing virus maps points of entry through entire female reproductive tract for first time.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Designing Better Drugs
A rational drug engineering approach could breathe new life into drug development.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
Factors Influencing Influenza Vaccine Effectiveness Uncovered
The long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited, new research suggests.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
New Model to Enhance Zika Virus Research
The model will allow researchers to better understand how the virus causes disease and aid in the development of antiviral compounds and vaccines.
Improving Flu Vaccine Effectiveness
NIH study finds factors that may influence influenza vaccine effectiveness.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!